Jan Basile to Risk Assessment
This is a "connection" page, showing publications Jan Basile has written about Risk Assessment.
Connection Strength
0.337
-
Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307.
Score: 0.082
-
One size does not fit all: the role of vasodilating beta-blockers in controlling hypertension as a means of reducing cardiovascular and stroke risk. Am J Med. 2010 Jul; 123(7 Suppl 1):S9-15.
Score: 0.055
-
Largest meta-analysis to date suggests that patients at risk for cardiovascular disease events derive benefit from antihypertensive therapy regardless of baseline blood pressure and to reduce vascular events, lowering blood pressure is more important than choice of antihypertensive drug class. J Clin Hypertens (Greenwich). 2009 Dec; 11(12):743-5.
Score: 0.053
-
Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction. J Cardiometab Syndr. 2006; 1(5):358-61.
Score: 0.041
-
Analysis of recent papers in hypertension. J Clin Hypertens (Greenwich). 2004 Feb; 6(2):96-101.
Score: 0.036
-
A statewide primary care approach to cardiovascular risk factor control in high-risk diabetic and nondiabetic patients with hypertension. J Clin Hypertens (Greenwich). 2004 Jan; 6(1):18-25.
Score: 0.035
-
Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance. Hypertension. 2016 10; 68(4):888-95.
Score: 0.021
-
Does prehypertension represent an increased risk for incident hypertension and adverse cardiovascular outcome? Hypertension. 2009 Nov; 54(5):954-5.
Score: 0.013